FASN and prostate carcinoma: Singh et al. evidenced that administration of sulforaphane (SFN) in preclinical mouse model results in dose-dependent downregulation of Acetyl-CoA Carboxylase 1 (ACC1) and Fatty Acid synthase (FASN) in human prostate cancer cell line; moreover, a decreased expression of these enzymes seems to be related to in vivo and in vitro PCa cell growth suppression.